Skip to contentK
Korro Bio, Inc.
K
KRROKorro Bio, Inc. Q3 2024 · 10-Q
Revenue$0.00$0.00no prior Q3 2023 on file Net Income-$21.00M-$21.00MN/M vs Q3 2023 EPS Diluted-$2.26-$2.26N/M vs Q3 2023 Operating Income-$23,292,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Korro Bio, Inc. · CIK 1703647 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$20,973,000N/M ended Sep 30, 2024 · filed Nov 12, 2024 · 43 d after period end